Combined use of ribavirin and interferon beta in demyelinating diseases

A kind of technology of interferon, application, application in the field of the compound represented by general formula, treatment and/or prevention of demyelinating diseases such as multiple sclerosis

Inactive Publication Date: 2006-04-19
APPL RES SYST ARS HLDG NV
View PDF20 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0040] However, no one in this technical field has considered the combination of ribavirin and IFN-β for the treatment of demyelinating diseases

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Combined use of ribavirin and interferon beta in demyelinating diseases
  • Combined use of ribavirin and interferon beta in demyelinating diseases
  • Combined use of ribavirin and interferon beta in demyelinating diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0145] Effects of ribavirin alone or in combination with IFN-β in in vivo models of multiple sclerosis

[0146] The established multiple sclerosis (MS) animal model was used to analyze the effect of ribavirin alone or in combination with IFN-β on disease development. The experimental autoimmune encephalomyelitis (EAE) model is a mouse model of chronic demyelination. The method used to induce EAE in mice was adapted from the protocol published by Sahrbacher et al. (1998).

[0147] EAE Induction Protocol

[0148] mouse

[0149] Breed, strain, substrain and sex: C57 BL / 6JICO female mice from the colony of IFFA CREDO (Saint Germain sur l'Arbresle, France) were provided by Charles River Italia (Calco, Lecco, Italy).

[0150] Age and weight (random): about 8 weeks old; 18-22g

[0151] Housing: Animals were housed in cages as follows:

[0152] - 10 animals per cage, placed in an air-conditioned room

[0153] -Temperature: 22℃±2

[0154] -Relative Humidity: 55%±10

[0155] - ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
concentrationaaaaaaaaaa
Login to view more

Abstract

The present invention is in the field of neurological disorders. It relates to the use of a compound of formula (I) in combination with an interferon (IFN) for the manufacture of a medicament for treatment and / or prevention of a demyelinating disease. In particular, it relates to the use of a combination of Ribaririn and IFN-beta for treatment and / or prevention of a demyelinating disease, such as multiple sclerosis.

Description

technical field [0001] The present invention belongs to the field of nervous system diseases and relates to compounds represented by general formula (I) [0002] [0003] Use in combination with interferon (IFN) in the manufacture of medicines for treating and / or preventing demyelinating diseases. In particular, it relates to the use of ribavirin in combination with IFN-β in the treatment and / or prevention of demyelinating diseases such as multiple sclerosis (MS). Background of the invention [0004] Demyelinating diseases are diseases involving the myelin sheath of the nervous system. Myelin sheath covers many nerve fibers and consists of layers of lipoproteins formed in juveniles. Myelin is formed by the oligodendrocytes of the central nervous system and facilitates the transmission of nerve impulses along axons. [0005] Many inborn errors of metabolism (eg, phenylketonuria, other aminoacidurias; Tay-Sachs, Nie-Peter, and Gaucher's diseases; Hurler's syndrome) 'ssy...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/7056A61K38/21A61K31/00A61K45/06
CPCA61K31/7056A61K45/06A61K31/00A61K38/215A61P25/00A61P31/12A61P43/00A61K2300/00A61K38/21
Inventor G·德鲁卡
Owner APPL RES SYST ARS HLDG NV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap